Baxter International (BAX): It's been a tough year for this medical supply giant, with a stock down 2.4% so far in 2015. But the turn may finally be at hand because the company is now set to spin off its bioscience division.

As it's currently configured, Baxter is a difficult company to figure value. It derives 60% of its sales from medical products like pre-filled syringes, vaccines and infusion pumps, while 40% of its revenue stem from its bioscience products.

In 2014, Baxter's earnings fell below its guidance, prompting the company in 2015 to stop issuing guidance altogether. The questions were raised about the safety of its 3% dividend yield, sending shares to 18 months lows.

But then Baxter announced it will spin off its bioscience division as a company called Baxalta, news that has been sending shares higher ever since.

As two separate entities, Baxter will be a cleaner, simpler story, Cramer noted, something that money managers will be able to easily value and will gravitate to thanks to easy comparisons and a peaking of the U.S. dollar.